Tobin Schilke - Dec 15, 2022 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role: CFO
Signature: /s/ Dwight Moxie, Attorney-in-Fact
Stock symbol: RVNC
Transactions as of: Dec 15, 2022
Transactions value $: -$33,476
Form type: 4
Date filed: 12/16/2022, 03:12 PM
Previous filing: Mar 9, 2023
Next filing: Jan 3, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RVNC	Common Stock	Tax liability	-$33.5K	-1.56K	-2.45%	$21.50	61.9K	Dec 15, 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares withheld by and surrendered to the Issuer on December 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award ("RSA") for 4,500 shares. The RSA vests in four equal annual installments from December 15, 2018, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) on each vesting date.

Content

Represents the number of shares withheld by and surrendered to the Issuer on December 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award ("RSA") for 4,500 shares. The RSA vests in four equal annual installments from December 15, 2018, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) on each vesting date.